Results 81 to 90 of about 4,245 (206)

Figure S1 from The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy

, 2018
Consort diagram of the study population. At the beginning of the analyses 421 patients, treated with peptide receptor radionuclide therapy (PRRT), were assessed. Patients who did not meet the inclusion criteria were excluded.
Maria A. Gonzalez-Carmona (9406151), Peter Brossart (640482), Markus Essler (344421), Karin Mayer (15012672), Christian P. Strassburg (7162190), Rolf Fimmers (271452), Hojjat Ahmadzadehfar (714757), Anna Yordanova (15012666), Marcel M. Wicharz (15012669)   +8 more
core   +1 more source

European Society of Neuroendocrine Tumors (ENETS) 2025 guidance paper for lung and thymic carcinoids

Journal of Neuroendocrinology, Volume 38, Issue 4, April 2026.
Abstract This ENETS guidance paper, developed by a multidisciplinary working group, provides up‐to‐date and practical advice on the diagnosis and management of lung and thymic carcinoids, based on recent developments and study results. These recommendations aim to provide practical recommendations for the diagnosis, treatment and follow‐up of these ...
Eric Baudin, Alice Durand, Wieneke Buikhuisen, Jaume Capdevila, Martyn Caplin, Christophe M. Deroose, Clarisse Dromain, Antongiulio Faggiano, Pier Luigi Filosso, Gregory Kaltsas, Marco Volante, Thomas Walter, Rocio Garcia‐Carbonero   +12 more
wiley   +1 more source

New Developments in Peptide Receptor Radionuclide Therapy

, 2019
Peptide Receptor Radionuclide Therapy (PRRT) is an established treatment for non-operable or metastatic neuroendocrine neoplasms that express highly and frequently somatostatin receptors.
NICOLAS Guillaume, SCHOTTELIUS Margret, FANI Melpomeni, MORGENSTERN Alfred   +3 more
core   +1 more source

Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report

Frontiers in Oncology
Meningiomas are the most common primary intracranial tumor in adults. Beyond surgery and radiation, no standard of care therapy exists. Meningiomas overexpress somatostatin receptor 2 (SSTR2), providing the rationale for somatostatin analogue-based ...
Carlen A. Yuen, Carlen A. Yuen, Mahbod Jafarvand, David O. Kamson, David O. Kamson, Eleanor Chu, Eleanor Chu, Jennifer E. Soun, Jennifer E. Soun, William H. Yong, Frank P. Hsu, Frank P. Hsu, Hansen Bow, Hansen Bow, Michelle Zheng, Shyam M. Srinivas   +15 more
doaj   +1 more source

Recommendations for bone‐directed therapy in patients with neuroendocrine tumour skeletal metastases at the New Zealand National Neuroendocrine Tumour Multidisciplinary Meeting

Internal Medicine Journal, Volume 56, Issue 3, Page 465-468, March 2026.
Abstract The role of anti‐resorptive agents in patients with bone metastases from neuroendocrine neoplasms is unclear. Our aim was to review bone‐specific treatment recommendations by the New Zealand National Neuroendocrine Tumour Multidisciplinary Meeting (MDM).
Gayle Radley, Marianne S Elston, Ben Lawrence, Veronica Boyle   +3 more
wiley   +1 more source

Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions

, 2022
This review article summarizes findings published in the last years on peptide receptor radionuclide therapy in GEP NENs, as well as potential future developments and directions.
Stefan Prado-Wohlwend, Juan F. Merino-Torres, Angel Segura, Pilar Bello, Maria I. del Olmo-García   +4 more
core   +1 more source

Metastatic large cell neuroendocrine carcinoma of larynx: Individualizing tumor biology by dual tracer positron emission tomography/computed tomography (68Ga-DOTATATE and 18F-fluorodeoxyglucose) molecular imaging and disease stabilization following 177Lu-DOTATATE peptide receptor radionuclide therapy after initial progression on chemoradiotherapy

World Journal of Nuclear Medicine, 2019
Debate exists on the disease biology and course of primary large cell neuroendocrine carcinoma (LCNEC) of larynx, being classified as a variant of atypical carcinoid by the World Health Organisation-2005 classification, while literature of its aggressive
Sonali Jadhav, Sandip Basu
doaj   +1 more source

Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.

European review for medical and pharmacological sciences, 2010
Clinical experience with the radiolabeled somatostatin analogues 90Y-DOTATOC and, more recently, 177Lu-DOTATATE, is ongoing since more than a decade in few centers. Dosimetric studies demonstrated that 90Y-DOTATOC and 177Lu-DOTATATE are able to deliver high doses to somatostatin receptor sst2-expressing tumors and low doses to normal organs.Clinical ...
Bodei, L., PEPE, GIOVANNI, Paganelli, Giovanni   +2 more
openaire   +2 more sources

Follow‐up is not justified in patients with typical lung carcinoids without lymph node involvement treated with curative intent: A Danish Multi‐ENETS Center of Excellence Study

Journal of Neuroendocrinology, Volume 38, Issue 3, March 2026.
Abstract Typical carcinoids (TC) are neuroendocrine malignancies of the lung with low risk of recurrence and a favorable prognosis. It is unclear whether lymph node status and tumor size affect the recurrence risk. Following radical surgery, current guidelines recommend comprehensive follow‐up including regular computed tomography (CT) imaging.
Tobias Stemann Lau, Patrick Soldath, Karina Stubkjær Rewitz, Peter Jepsen, Ulrich Knigge, Seppo W. Langer, René Horsleben Petersen, Mikkel Andreassen, Gitte Dam   +8 more
wiley   +1 more source

Efficacy of ¹⁷⁷Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study

Current Oncology, 2020
Peptide receptor radionuclide therapy (PRRT) has been recently established as a treatment option for progressive gastro-entero-pancreatic neuroendocrine tumors (NETs) including four 200 mCi induction cycles. The purpose of this phase 2 trial is to expand
Golmehr Sistani, Duncan E. K. Sutherland, Amol Mujoomdar, Daniele P. Wiseman, Alireza Khatami, Elena Tsvetkova, Robert H. Reid, David T. Laidley   +7 more
doaj   +1 more source